MULTIPLE SYSTEM ATROPHY - PARKINSONIAN SUBTYPE (MSA-P)

Clinical trials for MULTIPLE SYSTEM ATROPHY - PARKINSONIAN SUBTYPE (MSA-P) explained in plain language.

Never miss a new study

Get alerted when new MULTIPLE SYSTEM ATROPHY - PARKINSONIAN SUBTYPE (MSA-P) trials appear

Sign up with your email to follow new studies for MULTIPLE SYSTEM ATROPHY - PARKINSONIAN SUBTYPE (MSA-P), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 3 Not yet recruiting 1

Doctors test direct brain injection to fight rare neurological disease

Disease control Not yet recruiting

This is an early-stage study to see if a single injection of new brain cells (NouvNeu001) is safe and might help control symptoms of Multiple System Atrophy, a rare and serious neurological disease. It will involve 9 patients who are still able to walk with minimal assistance. Re…

Matched conditions: MULTIPLE SYSTEM ATROPHY - PARKINSONIAN SUBTYPE (MSA-P)

Phase: PHASE1 • Sponsor: iRegene Therapeutics Co., Ltd. • Aim: Disease control

Last updated Mar 31, 2026 12:10 UTC

MULTIPLE SYSTEM ATROPHY - PARKINSONIAN SUBTYPE (MSA-P)

Get alerted when new MULTIPLE SYSTEM ATROPHY - PARKINSONIAN SUBTYPE (MSA-P) trials appear

Doctors test direct brain injection to fight rare neurological disease